secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOTRICITY INC. (BTCY)
CIK:        0001630113
Form:       8-K
Filed at:   2021-08-17T23:59:59+00:00
Accession:  0001493152-21-020445
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biotricity Q1 revenue $1.76M, up 290% YoY, 9th consecutive triple-digit growth quarter
--------------------------------------------------------------------------------

- Revenue $1.76M for Q1 FY2022, up 290% vs. Q1 FY2021; sequential growth 49%.
- Operating expenses $4.2M, up only 17% YoY; R&D spend $590K, up 39%.
- Company projects continued revenue growth into FY2023; awaiting FDA approval for Biotres holter product.
- Gross margin or net income figures not disclosed; Company remains early-stage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630113/000149315221020445/0001493152-21-020445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630113/000149315221020445/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-020445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer